Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | AOC2 | O75106 | 3/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19224661 | 0.83 | MAPK8 (0.39) | MAPK8MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL604117 | 0.82 | MAPK8 (0.43) | MAPK8MEN1KMT2ACYP1A2CYP2C9 | |
| SCHEMBL965596 | 0.81 | AOC2 (0.58) | MAPK8MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL13329774 | 0.79 | KMT2A (0.53) | MAPK8MEN1KMT2ASIGMAR1SMYD3 | |
| SCHEMBL754150 | 0.79 | GAA (0.63) | MAPK8KMT2AAOC2GAAAOC3 | |
| SCHEMBL21672231 | 0.79 | KMT2A (0.53) | MAPK8MEN1KMT2ASIGMAR1SMYD3 | |
| SCHEMBL26542658 | 0.78 | P2RX7 (0.41) | MAPK8KMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL8640586 | 0.76 | TACR1 (0.55) | MEN1KMT2ASMYD3IDO1KDM4E | |
| SCHEMBL21981007 | 0.76 | MEN1 (0.50) | MAPK8MEN1KMT2ASIGMAR1GAA | |
| Hydrochloric Acid SCHEMBL26127531 | 0.76 | P2RX7 (0.40) | MAPK8KMT2ACYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912687-B2 | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof | Board of Trustees of the Southern Illinois University (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912687-B2 | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof | Board of Trustees of the Southern Illinois University (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912687-B2 | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof | Board of Trustees of the Southern Illinois University (US) | 2024-02-27 | — | — | US | disclosed |
| EP-3634406-B1 | 3,4,5-TRISUBSTITUTED-1,2,4-TRIAZOLES AND 3,4,5-TRISUBSTITUTED-3-THIO-1,2,4-TRIAZOLES AND USES THEREOF | BOARD OF TRUSTEES OF THE SOUTHERN ILLINOIS UNIV ON BEHALF OF SOUTHERN ILLINOIS UNIV EDWARDSVILLE (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-3634406-B1 | 3,4,5-TRISUBSTITUTED-1,2,4-TRIAZOLES AND 3,4,5-TRISUBSTITUTED-3-THIO-1,2,4-TRIAZOLES AND USES THEREOF | BOARD OF TRUSTEES OF THE SOUTHERN ILLINOIS UNIV ON BEHALF OF SOUTHERN ILLINOIS UNIV EDWARDSVILLE (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20230002336-A1 | MrgprX2 Antagonists and Uses Thereof | DERMIRA, INC. | 2023-01-05 | — | — | US | disclosed |
| EP-4055011-A1 | MRGPRX2 ANTAGONISTS AND USES THEREOF | Dermira, Inc (US) | 2022-09-14 | — | — | EP | disclosed |
| CN-114728919-A | MrgprX2 antagonists and uses thereof | 德米拉公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20220002274-A1 | 3,4,5-Trisubstituted-1,2,4-Triazoles and 3,4,5-Trisubstituted-3-Thio-1,2,4-Triazoles and Uses Thereof | Board of Trustees of the Southern Illinois University (US) | 2022-01-06 | — | — | US | disclosed |
| US-20220002274-A1 | 3,4,5-Trisubstituted-1,2,4-Triazoles and 3,4,5-Trisubstituted-3-Thio-1,2,4-Triazoles and Uses Thereof | Board of Trustees of the Southern Illinois University (US) | 2022-01-06 | — | — | US | disclosed |
| EP-3634406-A2 | 3,4,5-TRISUBSTITUTED-1,2,4-TRIAZOLES AND 3,4,5-TRISUBSTITUTED-3-THIO-1,2,4-TRIAZOLES AND USES THEREOF | Board of Trustees of The Southern Illinois University on behalf of Southern Illinois University Edwardsville (US) | 2020-04-15 | — | — | EP | disclosed |
| WO-2018209267-A2 | 3,4,5-TRISUBSTITUTED-1,2,4-TRIAZOLES AND 3,4,5-TRISUBSTITUTED-3-THIO-1,2,4-TRIAZOLES AND USES THEREOF | BOARD OF TRUSTEES OF THE SOUTHERN ILLINOIS UNIVERSITY ON BEHALF OF SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE (US) | 2018-11-15 | — | — | WO | disclosed |
| EP-2278878-A1 | 2-ARYL GLYCINAMIDE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20110003794-A1 | Naphthyridine Integrase Inhibitors | GSK LLC | 2011-01-06 | — | — | US | disclosed |
| US-7812016-B2 | Naphthyridine integrase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2010-10-12 | — | — | US | disclosed |
| WO-2009137657-A1 | 2-ARYL GLYCINAMIDE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-12 | — | — | WO | disclosed |
| EP-1622615-A4 | NAPHTHYRIDINE INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20070142365-A1 | Naphthyridine integrase inhibitors | GSK LLC | 2007-06-21 | — | — | US | disclosed |
| EP-1622615-A2 | NAPHTHYRIDINE INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004101512-A2 | NAPHTHYRIDINE INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003794-A1 | Naphthyridine Integrase Inhibitors | PCNA, SAMHD1, NTPCR | MAPK8 2537/4885MEN1 4802/4885KMT2A 1772/4885 |
| US-20070142365-A1 | Naphthyridine integrase inhibitors | PCNA, SAMHD1, NTPCR | MAPK8 2537/4885MEN1 4802/4885KMT2A 1772/4885 |
| US-20220002274-A1 | 3,4,5-Trisubstituted-1,2,4-Triazoles and 3,4,5-Trisubstituted-3-Thio-1,2,4-Triazoles and Uses Thereof | SSTR4, SSTR3, SSTR5 | MAPK8 1881/4885MEN1 1354/4885KMT2A 3857/4885 |
| US-20230002336-A1 | MrgprX2 Antagonists and Uses Thereof | MRGPRX2, MRGPRX1, MRGPRX4 | MAPK8 3277/4885MEN1 3172/4885KMT2A 3840/4885 |
| US-11912687-B2 | 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof | SSTR4, SSTR5, SSTR3 | MAPK8 1883/4885MEN1 1253/4885KMT2A 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.